Previous 10 | Next 10 |
March 26, 2019 Palm Beach, FL – March 26, 2019 – Research for the cure for cancer has become this generation’s version of President John F. Kennedy’s May 25, 1961 proclamation to “… landing a man on the Moon and returning him safely”. ...
I’ve been following Achillion Pharmaceuticals ( ACHN ) for quite some time, but became more interested after the company reported positive results of its factor D inhibitor ACH-4471 in two rare diseases – PNH and C3G. The problem with PNH is that the results aren’t goo...
ChemoCentryx, Inc. (CCXI) Q4 2018 Earnings Conference Call March 11, 2019 05:00 PM ET Company Participants William Slattery - Investor Relations, Burns McClellan Inc. Thomas Schall - Chairman, President and Chief Executive Officer Susan Kanaya - Executive Vice President, Chief Fi...
The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2018 Q4 earnings Read more ...
ChemoCentryx, Inc. (NASDAQ: CCXI ): Q4 GAAP EPS of -$0.21 beats by $0.06 . More news on: ChemoCentryx, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Strong Progress Across Company’s Orphan Disease Franchise of Novel Renal and Dermal Therapeutics -- -- Pivotal top-line data expected from ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis, Q4 -- -- Launched AURORA clinical t...
MOUNTAIN VIEW, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter 2018 financial results will be released after market close on Monday, March 11, 2019. ChemoCentryx executive management will host a conference call...
MOUNTAIN VIEW, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 10:30 a...
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +34.76% Cumulative Gain by Friday of the Week: -1.97% We are still seeing that selling the breakout stocks prior to the end of the fixed 5-day measurement period is the most profitable 1 week strategy. Also as I...
ChemoCentryx ( CCXI +0.3% ) has withdrawn its marketing application in Europe seeking conditional approval for avacopan (formerly CCX168) for the treatment of ANCA-associated vasculitis, an autoimmune disorder characterized by the inflammation and destruction of small vessels, a filing sub...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...